Waldenstrom Macroglobulinemia — Trials

Waldenstrom Macroglobulinemia — Trials · CancerIndex

Clinical trials

Registered studies

308 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 59
Recruiting: 26
Ph III recruiting: 2
Growth YoY: —
Industry share: 39%
Top sponsor: Christian Buske
Termination share: 30.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (53)

clinicaltrialsPublishedShowing 151–161 of 161 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00064246	Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder	completed	Phase 1 / Phase 2	28	National Cancer Institute (NCI)NIH	1	Jan 25, 2013	clinicaltrials
NCT00005950	506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma	terminated	Phase 2	111	National Cancer Institute (NCI)NIH	1	Jan 23, 2013	clinicaltrials